SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults

• Biological: Staphylococcus aureus 4-antigen vaccine
  
  a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
  Other Name: SA4Ag
• Biological: Placebo
  
  a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm

• Experimental: SA4Ag
  
  Staphylococcus aureus 4-antigen vaccine
  Intervention: Biological: Staphylococcus aureus 4-antigen vaccine
• Placebo Comparator: Placebo
  
  a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
  Intervention: Biological: Placebo

Inclusion Criteria:

1. Japanese male and female adults aged 20 to <86 years,
2. Determined as healthy by the investigator (Subjects with preexisting chronic medical conditions determined to be stable may be included),
3. Must be available for the 12 month duration of the study,
4. Subjects must agree to use an acceptable method of birth control for 3 months after study vaccination (if the subject or the subject's partner are/is capable of having children).

Exclusion Criteria:

1. Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components,
2. Unstable or serious chronic medical condition that would increase the subject's risk of participation,
3. Immune system suppression or treatment with medications that suppress the immune system,
4. Receipt of blood products or immunoglobulins within the past 12 months,
5. Any infection proven or suspected to be caused by S.aureus within the past 6 months,
6. A staff member at this site nor a relative of those site staff members, nor a sponsor's employee directly involved in the conduct of this research study,
7. Living in a nursing home, long-term care facility or other institution or requiring any types of nursing care,
8. A pregnant or a breast feeding woman.